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Abstract
Background: CRX is a homeobox transcription factor whose expression and function is critical to maintain retinal and pineal
lineage cells and their progenitors. To determine the biologic and diagnostic potential of CRX in human tumors of the retina
and pineal, we examined its expression in multiple settings.
Methodology/Principal Findings: Using situ hybridization and immunohistochemistry we show that Crx RNA and protein
expression are exquisitely lineage restricted to retinal and pineal cells during normal mouse and human development. Gene
expression profiling analysis of a wide range of human cancers and cancer cell lines also supports that CRX RNA is highly
lineage restricted in cancer. Immunohistochemical analysis of 22 retinoblastomas and 13 pineal parenchymal tumors
demonstrated strong expression of CRX in over 95% of these tumors. Importantly, CRX was not detected in the majority of
tumors considered in the differential diagnosis of pineal region tumors (n=78). The notable exception was
medulloblastoma, 40% of which exhibited CRX expression in a heterogeneous pattern readily distinguished from that
seen in retino-pineal tumors.
Conclusions/Significance: These findings describe new potential roles for CRX in human cancers and highlight the general
utility of lineage restricted transcription factors in cancer biology. They also identify CRX as a sensitive and specific clinical
marker and a potential lineage dependent therapeutic target in retinoblastoma and pineoblastoma.
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Introduction
Pineal parenchymal tumors predominantly affect children, and
account for approximately one-quarter of all neoplasms of the
pineal region [1]. These tumors exhibit a spectrum of clinical
aggressiveness that include pineocytomas, which are low-grade
well-differentiated and indolent tumors often with large pine-
ocytomatous rosettes; pineoblastomas, which are high-grade
poorly-differentiated aggressive embryonal tumors with dense
sheets of poorly differentiated small cells and pineal parenchymal
tumors of intermediate differentiation (PPTID), which have an
intermediate grade and prognosis[2–7]. The appropriate patho-
logic classification and grading of tumors of the pineal region is
essential for determining clinical management and prognosis[8],
however, the diagnostic evaluation is often difficult due to the
inherently small size of the biopsies for diagnosis and the wide
array of tumor types that can involve the pineal gland[3,9]. The
most common tumors entering the differential diagnosis are CNS
germ cell tumors, primitive neuroectodermal tumors, gliomas,
atypical teratoid/rhabdoid tumors and anaplastic ependymo-
ma[2,6,10]. However, specific markers which can positively
identify all pineal lineage tumors are generally lacking in clinical
practice. In addition, research into the biology and treatment of
these neoplasms has been severely hindered by the rare nature of
the tumors, the lack of primary tissue available for study, and the
scarcity of relevant cell lines or mouse models of the disease. Each
of these research areas would greatly benefit from the discovery of
reliable markers of the disease.
The pineocytes of the pineal and the cone and rod photoreceptors
of the retina share histological, ultrastructural, immunohistochem-
ical and pathologic features. Histologically, the human pineal gland
shows rosettes resembling those of the developing retina[11].
Ultrastructurally evaluation of pineal parenchymal tumors variably
reveals some evidence of photoreceptor differentiation including
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intracytoplasmic lumen, microtubular sheaves, and vesicle-crowned
and annulate lamellae [12–15] but such features are not present
reliably enough for routine clinical diagnosis. Pineal parenchymal
tumors have been shown to express antigens found in the retina
including retinal S-antigen[16,17], transducin[18,19], and inter-
photoreceptor retinoid-binding protein, rod opsin, cone opsin, and
cellular retinaldehyde-binding protein[20]. Conversely, normal
human retina and retinoblastoma express retinal and pineal antigens
consistent with incomplete retinal lineage differentiation, and a bias
towards cone photoreceptor antigens[21]. The common lineage
connection between the pineal and retina is further exemplified by
the occurrence of pineoblastoma in patients with retinoblastoma, a
phenomenon termed trilateral retinoblastoma[22–24]. This shared
heritage strongly suggests that lineage-restricted biomarkers found in
the developing retina and pineal may be useful not only as
immunohistochemical markers in the diagnosis of retino-pineal
tumors but possibly in the etiology or treatment of these tumors.
As a class, transcription factors are emerging as highly reliable
tools in the pathologic diagnosis of human solid tumors[25].
Recently, our group and others demonstrated that lineage-
restricted transcription factors such as OCT4 and NANOG are
robust markers for the diagnosis of germ cell tumors, including
those in the central nervous system[26–29]. Crx is an Otx-like
homeobox transcription factor critical for photoreceptor differen-
tiation and for maintenance of the transcriptional regulatory
networks essential for normal retinal development [30]and pineal
function[31–33]. Mutations in the human CRX gene lead to
photoreceptor degeneration and the retinal diseases cone-rod
dystrophy 2 (CORD2), Leber congenital amaurosis type VII
(LCA7), and retinitis pigmentosa, late onset dominant[34–38].
Consistent with these findings, Crx null mice demonstrate a
lineage dependent role for this TF in proper development of
retinal stem/progenitor cells leading to susequent photoreceptor
degeneration[39]. In addition, while the pineal gland appears
grossly normal in post-natal Crx null mice, pineal-specific gene
expression is reduced and circadian entrainment is attenuated[39].
Little is known about CRX expression or function in human
cancer, although several studies have described its expression in
retinoblastoma cell lines. Given its restricted expression and
functional relevance in pineal and retinal cell lineages we sought to
more comprehensively establish whether CRX might serve as a
robust TF marker for research and digansotic evaluation of retino-
pineal tumors.
In this study we demonstrate expression of Crx in normal and
neoplastic cells of retinal and pineal lineage and demonstrate the
utility of immunohistochemistry for Crx in discriminating pineal
parenchymal tumors from other lesions that often enter the
differential diagnosis of pineal masses.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed in
the Declaration of Helsinki. All work on human tissues was conducted
on anonymous excess archival human material from the Departments
of Pathologyat Children’s Hospital Boston and Brigham and Women’s
Hospital. The research study was approved by the Children’s Hospital
Boston Institutional Review Board for Human Research and also the
Brigham and Women’s Hospital Institutional Review Board for
Human Research as an excess tissue protocol. The data were analyzed
anonymously and therefore both review boards did not require specific
written consent from patients for this study.
Tissue Samples
Paraffin blocks from surgical resection specimens spanning a 10
year period (1998–2008) were obtained as anonymous specimens
from Children’s Hospital, Boston and Brigham and Women’s
Hospital, Boston, in accordance with the regulations of the review
boards of both institutions for excess tissue. Diagnoses were
confirmed based on World Health Organization diagnostic
criteria. Surgical resection samples consisted of five normal pineal
tissue, three pineal cysts, five pineoblastoma, four pineocytoma,
four pineal parenchymal tumor of intermediate differentiation,
nine CNS germinoma, four CNS embryonal carcinoma, ten
medulloblastoma, five supratentorial primitive neuroectodermal
tumor, five atypical teratoid/rhabdoid tumor, five Langerhan’s
cell histiocytosis, five neurocytoma, 12 glioblastoma, 12 anaplastic
oligodendroglioma, five meningioma, five choroid plexus carcino-
ma, six anaplastic ependymoma, five metastatic carcinoma (one
lung adenocarcinoma, one ductal carcinoma of the breast, one
neuroendocrine carcinoma, one renal cell carcinoma and one
melanoma) and enucleation specimens of retinoblastoma. Paraffin
blocks of ten pineals from post-mortem examination were also
obtained from the archives of Brigham and Women’s Hospital.
The pineal tumor samples were consecutive samples that had
sufficient tissue present in the block for research use. The study
was designed in light of recommendations from the STARD
(STAndards for the Reporting of Diagnostic accuracy studies)
statement. http://www.stard-statement.org/
Slide Preparation, Immunohistochemistry and Scoring
Specimens were fixed in 10% buffered-formalin, four-micron
sections were generated from paraffin blocks and slides were
stained with hematoxylin and eosin (H&E). Serial sections of the
paraffin blocks were cut and these slides were used for
immunohistochemical studies. The antigen, clone, dilution,
antigen retrieval conditions and vendors of the primary antibodies
are listed in Table 1 and all antibodies are publicly available
Table 1. Antibody Panel Used In This Study.
Antigen Clone Dilution Antigen Retrieval Vendor
CRX Polyclonal Rabbit (H-120) 1:100 Citrate; Microwave Santa Cruz Biotechnology, Santa Cruz, CA
OCT3/4(POU5F1) Monoclonal Mouse (C-10; sc-5279) 1:2000 Citrate, Steamer Santa Cruz Biotechnology, Santa Cruz, CA
OLIG2 Polyclonal Rabbit (AB9610) 1:15K Citrate; pressure cooker Millipore
GFAP Polyclonal Rabbit (Z 0334) 1:20K Pressure cooker citrate DAKO
Synaptophysin Monoclonal Mouse (SY38) 1:200 no treatment DAKO
doi:10.1371/journal.pone.0007932.t001
CRX in Retino-Pineal Cancer
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and visualization was attained using the Envision Plus Detection
System (Dako, Carpinteria, CA). Competition experiments were
performed using recombinant proteins expressed in bacteria GST-
Crx and the unrelated protein GST-Cry1 (Abnova H00001406-
P01 and H00001407-P01) as well as Glutathione-S-Transferase
(GST) alone (Millipore 12–350). Equimolar amounts of protein
and anti-Crx antibody were incubated together for 30 minutes at
room temperature and then applied to tissue sections as described
above. Grading of immunoreactivity was based on the following
semiquantitative approach by two neuropathologists (SS and KL):
0, no tumor cells demonstrating nuclear (for Crx) or membranous/
cytoplasmic staining (for GFAP, Synaptophysin); 1+, ,5% of
tumor cells reactive; 2+, .5%–25% of tumor cells reactive; 3+,
.25%–50% of tumor cells reactive; 4+, .50%–75% of tumor
cells reactive; 5+, .75% of cells reactive.
Immunoblotting
50 ng and 20 ng of indicated proteins were spotted on
nitrocellulose membranes. Blocking was performed for 1 hr using
5% BSA in PBS-T, followed by application of rabbit polyclonal
anti-Crx antibody (H120; 1:400 dilution in 0.1%BSA/PBS-T) for
30 min, 3 washes with PBS-T and incubation with anti-rabbit
secondary antibody conjugated with HRP (1:5000 dilution in
0.1%BSA/PBS-T). Following an additional three washes with
PBS-T, the membrane was developed with chemiluminescent
substrate (Thermo, SuperSignal West Pico 34078).
In Situ Hybridization
Analysis of the expression pattern of Crx mRNA was conducted
using GenePaint.org, an interactive publically available in situ
hyrbidization (ISH) atlas of gene expression patterns in mouse
embryos at developmental stage E14.5 (NMRI albino and
C57BL/6 strains) and post-natal (P7) mouse brain (C57BL/6
strain). As described (http://www.genepaint.org/Frameset.html),
gene expression was detected using digoxigenin-labeled antisense
riboprobes generated by in vitro transcription from DNA templates
and images and associated meta-data are deposited in a searchable
public database (http://www.genepaint.org)[40,41]. In situ hy-
bridization studies for localization of CRX in post-natal mouse
retina was performed according to standard protocols[40,41].
Sequences for the DNA template used for in vitro transcription of
the RNA probe were generated with primer sets available at
http://www.genepaint.org.
Animal Procedures
For immunohistochemistry studies, tissue specimens including
brain and eye were harvested from E14.5 mouse pups that
either had one (Crx+/2) or both (Crx 2/2) alleles disrupted [39].
The specimens were snap frozen in liquid nitrogen and sections
were prepared by cryostat sectioning. Genotyping was performed
as previously described [39] and using probes designed by
Transnetyx Inc.
Animal Welfare Statement
All animals were handled in strict accordance with good animal
practice as defined by the European Communities Council
Directive of November 24, 1986 (86/609/EEC) and under
authorization of Az 32.22/Vo (‘‘Ordnungsamt der Stadt Go ¨ttin-
gen’’). All animals were euthanized for analysis using procedures
approved by the appropriate institutional animal welfare
committee.
Expression Profiling Analysis
Expression profiling analysis of cell lines was performed using
the publicly available Oncomine resource (http://www.oncomine.
org/main/mianx,jsp) [42]and the publicly available datasets
contained within the Oncomine database. Analysis was done
using the t-test method for determining significance of CRX
expression across multiple datasets for normal and cancer cell
lines. All data was collected using U133 Plus 2.0 Affymetrix arrays.
Global cancer cell line analysis was done using an unpublished but
publicly available dataset created by Wooster et. al. in collabora-
tion with GlaxoSmithKline which contained data from 316 cancer
cell lines. Representative cell lines of pineal origin were not present
in this dataset.
Meta-analysis of Crx expression was also assessed in a wide
range of tumor types. Raw data files downloaded from public
resources were first processed using the MAS5.0 algorithm
implemented in Bioconductor to obtain detection calls and the
39 to 59 signal ratios for control probesets: GAPDH and b-
ACTIN. All the CEL files were processed using the RMA
algorithm implemented in Bioconductor to generate normalized
expression values. Expression values were scaled by computing the
median expression value for each sample and then processed using
a custom script to scale the RMA-derived expression values such
that each array will have the same median intensity. Expression
profiling data from 1936 individual tissue samples and 929
individual cell line preparations were evaluated in this manner.
Sequence Alignment
Sequence alignment (Smith-Waterman algorithm) of human
CRX immunogen (amino acids 166 to 285) was performed with
OTX1 and OTX2. The alignment conservation annotation is
based on the AMAS method of multiple sequence alignment
analysis[43]. The image was generated using Jalview 2.4.
Results
Crx mRNA Is Restricted to the Retina and Pineal
To determine the degree of lineage restriction of Crx during
development, we performed in situ hybridization on whole animal
sections to detect Crx RNA at embryonic and postnatal stages. In
14.5 days post coitus NMRI mouse embryos (E14.5) Crx
expression was restricted to the developing ventricular zone (VZ)
progenitor cells of the retina and the pineal gland (Fig. 1A-D). At 7
postnatal days (P7), strong signal was detected in the outer nuclear
layer of the retina with weak signal present in the inner nuclear
layer (data not shown). In the brain of P7 mice, strong Crx RNA
expression was mainly restricted to the pineal gland in C57BL/6
mice (Fig. 1E, 1F). Weak expression of Crx RNA was, however,
also detected in the soft tissues of the face (Fig. 1A) and in a thin
layer of the periventricular VZ progenitors of the developing
posterior cerebral hemispheres (Fig. 1C). A similar pattern of
expression to that seen in the NMRI embryo was also observed at
stage E14.5 in C57BL/6 mouse embryos with a riboprobe
recognizing a different portion of the Crx transcript (data not
shown) in images obtained from the genepaint database (http://
www.genepaint.org)[40,41].
Characterization of Anti-CRX Antibody H120
In light of the fact that CRX protein expression in situ has not
been extensively analyzed, we sought to determine whether CRX
expression might be similarly restricted in human at the protein
level. To validate the specificity of the rabbit polyclonal antibody
used in these studies (Table 1; Santa Cruz H120 anti-Crx) for
CRX in Retino-Pineal Cancer
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immunoblotting and immunohistochemistry approaches.
OTX1 and OTX2 are the proteins with the highest sequence
identity to CRX in the genome of human and mouse. An
alignment of the protein sequences in the region of human CRX
that was used to generate the polyclonal antibody (amino acids 166
to 285) reveals that the overall identity between CRX and OTX1
(30%) and OTX2 (40%) is low reducing the likelihood of antibody
cross reactivity (Fig. 2A). In fact in this region, homology is limited
to stretches of three amino acids or less (with only one region of
CRX and OTX1 sharing four amino acids), which is an
insufficient length to likely support significant cross-reactivity of
the antibody via a shared epitope.
We next performed immunoblots following SDS-PAGE resolu-
tion of lysates from human retina, human retinoblastoma cells and
293T cells with exogenously expressed Crx protein. Interestingly,
we were unable to detect any band corresponding to Crx in any of
these denatured lysates (data not shown). In fact no bands at all
(background) were detected under these conditions. Incubation of
the same Western blot with another antibody available through
Santa Cruz (Q17 monoclonal) detected a band of the appropriate
size. These findings led us to hypothesize that the H120 antibody
was recognizing a conformational epitope rather than a linear
epitope, a relatively frequent event according to published
studies[44]. To test this we performed dot blots of native (non-
denatured) GST-CRX protein purified from bacteria and were
successfully able to detect the native protein with the H120 Crx
antibody while we were unable to detect control unrelated proteins
or GST alone (Fig. 2B).
Since the H120 anti-Crx antibody recognizes a conformational
rather than a linear epitope, we further characterized the
specificity of the antibody in the context of in vivo staining. We
demonstrate that the H120 anti-Crx antibody recognizes a strong
signal in appropriate regions of the developing retina of E14.5
mice that are heterozygous for Crx (Crx +/2) but that the signal is
completely absent in the retina of Crx knockout mice (Crx 2/2)
which lack only the Crx protein through homologous recombina-
tion [39](Fig. 2C). In addition, the pattern of immunoreactivity
detected in the mouse CNS using the H120 anti-CRX antibody
(retina and pineal) mirrors the pattern of CRX mRNA expression
and not that of OTX1 and OTX2 mRNA expression as
determined by in situ hybdridization (Fig. S1). To further address
the specificity of the antibody in the context of human tissue, we
performed competition assays with purified CRX protein and
show on tissue sections of human retinoblastoma and adjacent
uninvolved retina that the immunostaining with the H120 anti-
Crx antibody can be completely competed away with 1:1 molar
amounts of purified GST-Crx protein in both normal retina and
the retinoblastoma tumor cells (Fig. 2D).
CRX Protein Is Highly Expressed in Human Retina and
Pineal
Having characterized the specificity of the antibody for
recognition of Crx, we turned to evaluating the pattern of
expression of CRX in the human eye and pineal. Analysis of
normal appearing adult human retina (Fig. 3A,3B) from eye
enucleation specimens showed robust expression of CRX protein
in 95% of cases (19/20). Expression was detected in nearly all of
the nuclei of cone and rod photoreceptor cells in the outer nuclear
layer (Fig. 3B). Weaker expression was demonstrated in the nuclei
of the inner nuclear layer (Fig. 3B) in the cells immediately
adjacent to the outer plexiform layer of the retina, consistent with
previously reported results[30,45–47]. This region of the inner
nuclear layer is populated predominantly by the nuclei of bipolar
Figure 1. Strong expression of Crx mRNA is highly restricted to
the retina and pineal during normal murine development. RNA
in situ hybridization using antisense riboprobes for Crx at developmen-
tal stage E14.5 in NMRI mouse embryos (Genepaint Set ID DA117)
demonstrates strong expression in the ventricular zone of the retina (A,
B) and in the developing pineal which appears as a diverticulum in the
diencephalic roof of the third ventricle (C, D). Crx in the brain of a P7
C57BL/6 mouse (Genepaint Set ID MH1082) demonstrates strong
expression restricted to the pineal primordium (E, F)[40,41].
doi:10.1371/journal.pone.0007932.g001
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cells (Fig. 3B).
Expression of CRX protein in the human pineal was also
evaluated by immunohistochemistry in eight pineal surgical
resection specimens that contained either normal pineal (n=5)
(Fig. 2C) or a pineal cyst (n=3) (Fig. 3E). In all eight specimens
intranuclear staining was present in .85% of pineocyte nuclei
(Fig. 3D, 3F). Gliotic regions composing the cyst wall were
negative for intranuclear CRX immunostaining (Fig. 3F) as were
inflammatory cells and endothelial and smooth muscle cells
composing blood vessels. To note, expression of CRX was
detected by immunohistochemistry in none of the ten post-
mortem pineal specimens evaluated. The presence of CRX in
surgically-derived pineal specimens but the absence of CRX
immunostaining in autopsy-derived tissue likely reflects the labile
nature of the antigen and highlights the importance of performing
CRX immunohistochemistry on recent resection specimens that
have undergone prompt formalin-fixation after resection.
CRX Is a Sensitive Marker for Retinoblastoma and Pineal
Parenchymal Tumors
CRX protein expression was evaluated by immunohistochem-
istry in 22 enucleation specimens for histologically confirmed
retinoblastoma (Fig 4A, 4C). 21 of the 22 cases (.95%)
demonstrated strong intranuclear CRX immunoreactivity in most
tumor cells (Fig 4B, 4D) with strong staining evident in both well-
differentiated regions demonstrating Flexner-Wintersteiner ro-
settes (Fig. 4D) as well as in moderately and poorly differentiated
regions (Fig. 4B). CRX immunostaining was negative in the
regions of optic nerve adjacent to the retinoblastoma (Fig. 4B,
lower right portion of field). CRX immunostaining was absent in
necrotic regions and often in morphologically viable cells
surrounding these necrotic regions. In addition, we noted CRX
expression was weak or absent in the central portion of large
tumors while the peripheral portions and the associated retina
demonstrated strong expression. These findings, in addition to the
absence of CRX staining in post-mortem pineal tissue, suggest that
the CRX antigen is moderately labile and needs to be evaluated in
well-fixed tissue.
CRX expression was also evaluated by immunohistochemistry
in 13 pineal parenchymal tumors that were classified according to
WHO criteria. Included among these were four pineocytoma
(W.H.O. Grade I) (Fig. 5A), four pineal parenchymal tumors of
intermediate differentiation (W.H.O. Grade II/III) (Fig. 5C), and
five pineoblastoma (W.H.O. Grade IV) (Fig. 5E). These tumors
had previously solely been evaluated with GFAP and synapto-
physin to arrive at a clinical diagnosis (Table 2). Twelve of the 13
cases demonstrated intranuclear staining for CRX (4 of 4
pineocytoma, Fig. 5B; 4 of 4 pineal parenchymal tumor of
intermediate differentiation, Fig. 5D; and 4 of 5 pineoblastoma
Fig. 5F). Four of the five pineoblastoma demonstrated intranuclear
staining in .50% of tumor cells, 3 of the 4 pineal parenchymal
Figure 2. Validation of antibody specificity. Sequence alignment (Smith-Waterman) of human CRX immunogen (amino acids 166 to 285) with
OTX1 and OTX2 (A) demonstrates low identity for the relevant epitope (,40%). Residue number 1 correpsonds with residue 166 of CRX. AMAS
conservation scores are listed below the alignment. Immunoblot of native, non-denatured GST-Crx, GST alone and with the unrelated protein GST-
Cry1 demonstrates robust specificity of the H120 antibody for native Crx (B). Immunohistochemical analysis using the H120 anti-Crx antibody
demonstrates strong reactivity in the developing retina of E14.5 mice, which are heterozygous for Crx (Crx +/2), while the signal is absent in the
retina of Crx knockout mice (Crx 2/2) (C). Competition assays with CRX protein on tissue sections of human retina and retinoblastoma (cells at top of
image) demonstrate the immunoreactivity of the H120 anti-Crx antibody is specifically competed away with 1:1 molar amounts of purified GST-Crx
protein in normal and tumor cells.
doi:10.1371/journal.pone.0007932.g002
CRX in Retino-Pineal Cancer
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staining in 50% of tumor cells and 3 of the 4 pineocytoma
demonstrated intranuclear staining in .50% of the tumor cells
(Table 2). The heterogeneity of CRX staining in a portion of the
tumor samples may reflect biological heterogeneity within these
tumors. Of these pineal parenchymal tumors, 12 of 13
demonstrated immunoreactivity for synaptophysin, currently the
most widely used marker of pineal tumors, in .75% of tumor cells
and 12 of 13 demonstrated immunoreactivity for GFAP, a glial
marker, in ,5% of tumor cells. Examination of serial sections
showed that the CRX staining correlated precisely to regions of
synaptophysin signal in a highly specific manner in 100% of cases.
In all, the data suggest that CRX is a sensitive diagnostic marker
for tumors of pineal lineage and can be used effectively along with
synaptophysin and GFAP in the diagnostic evaluation of these
tumors.
CRX Is a Specific Marker for Tumors of Pineal/Retinal
Lineages
The diagnosis of tumors of the pineal region is often difficult due
to the range of tumor types that can affect this region and the often
minute size of the biopsy that is provided for definitive diagnosis.
To investigate the specificity of CRX in the diagnosis of tumors of
pineal/retinal lineage, we performed immunohistochemistry for
CRX on a number of tumor types that frequently enter the
differential diagnosis of pineal masses (Fig. 6A–6F). Intranuclear
immunoreactivity was not detected in a broad range of tumors
Figure 3. CRX protein is highly expressed in the normal adult
human retina and pineal. Immunohistochemical analysis of CRX
expression demonstrates robust expression in the nuclei of cones and
rod cells in the outer nuclear layer (onl) as well as much weaker
expression in a subset of nuclei in the inner nuclear layer (inl) that abut
the outer plexiform layer (opl) of the adult human retina (A, B). This
region is populated predominantly by horizontal and bipolar cells. The
ganglion cell layer does not express CRX. Expression of CRX in the
pinealocytes of a surgically resected normal pineal gland (C, D) and
pineal cyst (E, F arrows). Gliotic regions composing the cyst wall do not
express CRX (lower left corner of E, F). Optic fiber layer (ofl), ganglion
cell layer (gcl), inner plexiform layer (ipl), inner segment (is), outer
segment (os), pineal cyst (pc). Original magnification 200x (A, B, E, F)
and 400x (C, D).
doi:10.1371/journal.pone.0007932.g003
Figure 4. CRX is a sensitive marker for retinoblastoma. Human
enucleation specimen with retinoblastoma (rb) abutting and infiltrating
a portion of optic nerve (A, opt), immunohistochemical staining for CRX
demonstrates robust expression in the nuclei of most all tumor cells
and an absence of CRX expression in cells of the optic nerve (B). 100x
original magnification. A higher magnification view of human
retinoblastoma demonstrating distinct Flexner-Wintersteiner rosettes
(C, D arrows) also reveals strong expression of CRX in tumor nuclei
particularly in rosettes (D). Original magnification 400x.
doi:10.1371/journal.pone.0007932.g004
Figure 5. CRX is a sensitive marker for tumors of pineal lineage.
Immunohistochemistry reveals robust intranuclear expression of CRX in
the nuclei of various tumors of pineal lineage: pineocytoma (A, B),
pineal parenchymal tumor of intermediate differentiation (C, D) and a
pineoblastoma (E, F). Original magnification, 400x.
doi:10.1371/journal.pone.0007932.g005
CRX in Retino-Pineal Cancer
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(Fig. 6A, 6B), nine germinoma (Fig. 6C, 6D), five primitive
neuroectodermal tumors (Fig. 6E, 6F), four embryonal carcinoma,
five choroid plexus carcinoma, six anaplastic ependymoma, five
metastatic carcinoma, five neurocytoma, five Langerhans cell
histiocytosis, five meningioma and 24 high-grade diffuse gliomas
(12 glioblastoma and 12 anaplastic oligodendrogliomas).
Pathologic distinction of medulloblastoma from pineoblastoma
can occasionally pose a clinical challenge given that these poorly
differentiated tumors are morphologically indistinguishable and
larger tumors may grow to involve both the superior cerebellum
and pineal regions. Interestingly, four of ten medulloblastoma
(Fig. 6G) demonstrated a subpopulation of scattered cells with
positive intranuclear CRX staining (Fig. 6H). Two of the cases
showed immunoreactivity in ,5% of the tumor cells, one case in
5–25% of tumor cells and one in 25–50% of tumor cells. While
this heterogeneous pattern of immunoreactivity is noteworthy,
none of the cases demonstrated the robust, uniform pattern of
CRX immunostaining most often seen in pineoblastoma.
A specific example of the practical diagnostic use of CRX
immunohistochemistry can be provided by a recent case evaluated
at Children’s Hospital, Boston of a high-grade neoplasm of the
pineal region (Fig. 7A). This tumor represented the frequent
diagnostic challenge presented by tumors of the pineal. This
particular tumor was identified as a high-grade neoplasm of
uncertain origin based on a minute surgical biopsy specimen. A
panel of lineage specific transcription factors including CRX
(pineal), OLIG2 (diffuse gliomas) and OCT4 (germ cell tumors)
were utilized to ‘‘decode’’ the lineage of the tumor. In this case
CRX and the germ cell transcription factor OCT4 were negative
and showed no intranuclear reactivity in tumor cells (Fig. 7B and
7C), while OLIG2 exhibited strong nuclear staining (Fig. 7D)
consistent with a high-grade glioma arising principally in the
pineal region.
As seen in Figure 7B, we also found that a low percentage of
tumors demonstrated weak granular cytoplasmic immunoreactiv-
ity for CRX. This pattern of cytoplasmic staining was particularly
seen in gliomas, Langerhans cell histiocytosis, central neurocyto-
ma, primitive neuroectodermal tumor and renal cell carcinoma. In
addition, the cytoplasm of lymphocytes demonstrated weak to
moderate immunoreactivity as noted in tumors bearing many of
these cells such as some germinoma. The cytoplasmic pattern of
staining appears to be consistent with cross-reactivity within the
endoplasmic reticulum and/or secretory granules and was not
considered to be specific staining.
Finally, to more broadly investigate the extent of CRX
expression across many types of cancer and normal tissues, we
performed a meta-analysis of expression profiling data from a wide
range of cancer tissues, normal tissue controls and cancer cells
lines using a wide sampling of publicly available datasets (Table
S1). Meta-analysis of 1,934 primary tumor and normal tissue
samples of various types revealed high levels of Crx expression was
restricted to a subset of medulloblastoma specimens, particularly
those of anaplastic subtype (Fig. 8A). Publicly available datasets
from retinoblastoma or pineoblastoma were not identified in this
analysis. Furthermore, analysis of a comprehensive panel of 318
different human cancer cell lines (Wooster et al.; Oncomine
database of transcriptome profiles (http://www.oncomine.
org)[42,48,49]) using both Oncomine analysis methods
(Figure 8B,C), as well as the normalization methods used in
tumor tissues above (Fig. S2) demonstrated that the highest relative
level of CRX expression was present in the sole retinoblastoma cell
line (Y79) present in the dataset (Fig. 8B and 8C) and that
moderate levels of CRX expression were also noted in two
medulloblastoma cell lines (D341-Med and D283-Med) and a
handful of other non-CNS tumor cell lines. Overall, the vast
majority of tumor lines showed no evidence of consistent
expression of CRX, including 8 glioma cell lines and 1 central
PNET cell line. No expression profiles of tumors or cell lines of
pineal parenchymal origin were available for comparison within
public databases.
Discussion
Advances in the study of the normal pineal and pineal region
tumors has been limited in part due to their very infrequent
occurrence, with tumors of the pineal region accounting for less
than 0.1% of all intracranial tumors. Here we hypothesized that
Table 2. Immunohistochemical Staining Results on Pineal Parenchymal Tumors.
Case Number Tumor Age (years) Gender CRX GFAP Synaptophysin
1 Pineocytoma 71 Female 2+ 05 +
2 Pineocytoma 56 Female 4+ 04 +
3 Pineocytoma 61 Male 4+ 04 +
4 Pineocytoma 54 Male 4+ 3+ 2+
5 PPTID 2 Male 4+ 04 +
6 PPTID 30 Male 2+ 04 +
7 PPTID 44 Female 4+ 05 +
8 PPTID 36 Female 4+ 04 +
9 Pineoblastoma 4 Male 4+ 1+ 5+
10 Pineoblastoma 12 Female 4+ 05 +
11 Pineoblastoma 13 Male 5+ 05 +
12 Pineoblastoma 9 Male 5+ 1+ 5+
13 Pineoblastoma 8 Female 0 0 4+
Table 2 Legend:
0 indicates no staining; 1+, ,5% tumor cells reactive; 2+, 5% to 25% tumor cells reactive; 3+, 26% to 50% tumor cells reactive; 4+, 51% to 75% tumor cells.
reactive; 5+, .75% tumor cells reactive. GFAP, Glial Fibrillary Acid Protein; Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID).
doi:10.1371/journal.pone.0007932.t002
CRX in Retino-Pineal Cancer
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7932lineage restricted transcription factors for retino-pineal progenitors
might represent useful diagnostic and investigational tools as has
been demonstrated in other cancers[28,29,50,51]. The molecular-
genetic similarity between the retina and pineal and the
remarkably restricted expression pattern of Crx mRNA suggested
a distinct opportunity for employing Crx as a candidate biomarker.
Our studies of RNA ISH in whole embryos and brain confirm the
remarkable lineage restiction of this gene across the whole mouse
embryo. Furthermore, our studies in human systems using IHC
and expression profiling data validate that such lineage restriction
is highly preserved in humans as well. Given that CRX protein
expression had not been previously as well studied, we find that the
RNA and protein expression are highly conserved with no
significant differences detected in our study.
From a diagnostic standpoint, we find that .90% of
retinoblastoma and .90% of pineal parenchymal tumors display
significant intranuclear expression of CRX while none of the
tumors entering the differential diagnosis of pineal masses display
intranuclear CRX immunoreactivity. These findings highlight that
CRX is both a sensitive and specific marker for tumors of pineal
and retinal lineage and that its use should be further evaluated for
routine application as an essential component of the standard
workup of tumors of the pineal region. Previous studies using non-
TF markers of photoreceptor lineage have also supported the
lineage conservation between tumors of these two regions, but due
to their non-nuclear and less consistent expression have found little
diagnostic acceptance in clinical practice[20,52]. These same
studies in the retina had concluded that retinoblastomas
represented a bias towards cone differentiation, and the presence
of strong CRX staining supports this given its more specific role in
development of cone photoreceptors[52]. Also, while immunohis-
tochemistry for CRX may be of practical utility in the
classification of biopsies of the central nervous system it may also
be valuable in unequivocally ascribing peripheral metastases in
bone marrow and elsewhere to a known primary ocular
retinoblastoma as well as in the evaluation of cerebrospinal fluid
cytological specimens in patients with retinoblastoma, pine-
oblastoma and pineal parenchyal tumor of intermediate differen-
tiation. Finally we find that CRX is a new sensitive and specific
marker for retinoblastoma and pineal parenchymal tumors that
should be useful in the diagnostic evaluation of pineal masses when
used as part of a panel of immunohistochemical markers including
synaptophysin and GFAP.
An interesting finding in this study is that CRX is expressed in a
heterogeneous subpopulation of cells in four out of the ten
medulloblastomas that were analyzed. Photoreceptor differentia-
tion has previously been demonstrated in medulloblastoma with
retinal S-antigen and rhodopsin antigens detected by immunohis-
tochemistry[53–55]. A recent study classifying medulloblastoma
based on gene expression profiles identified five molecular-genetic
subtypes, two of which demonstrated photoreceptor differentia-
tion[56]. These subtypes represented approximately 40% of
medulloblastoma cases, similar to our findings, and had increased
RNA expression of the photoreceptor transcription factors CRX,
NRL and NR2E3. In addition, they were associated with clinical
presentation at a younger age (,3 years of age) and more
aggressive biological behavior with an increased risk of metastases
Figure 7. Diagnostic use of lineage-specific transcription factor
‘‘code’’ in evaluation of a glioblastoma of the pineal region.
Examination of H&E stained sections of a pineal tumor reveals high-
grade histologic features somewhat suggestive of glioblastoma (A).
Immunohistochemistry showed nuclear CRX in normal pineocytes (red
arrow) that are infiltrated by the invasive tumor which is negative for
CRX (black arrow) (B). The germ cell marker OCT4 is absent in neoplastic
cells and in pineocytes (C). However, robust expression of OLIG2 is
evident in neoplastic cells but absent in infiltrated pineocytes (arrow)
(D). Original magnification 400x.
doi:10.1371/journal.pone.0007932.g007
Figure 6. CRX is a specific marker for tumors of retinal and
pineal lineage. Immunohistochemistry for CRX in tumors frequently
considered in the differential diagnosis of pineoblastoma including
atypical teratoid rhabdoid tumor (ATRT) (A, B), CNS germinoma (C, D)
and primitive neuroectodermal tumor (PNET) (E, F) reveals an absence
of staining. Immunostaining for CRX in classic medulloblastoma reveals
heterogeneous intranuclear staining in scattered cells in a subset of
tumors (G, H). Original magnification, 400x.
doi:10.1371/journal.pone.0007932.g006
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molecular heterogeneity of medulloblastoma [57,58] and suggest
that in addition to a role in the diagnosis of pineal and retinal
tumors, CRX immunohistochemistry may provide critical infor-
mation in determining subtype classification and poor prognosis in
cases of medulloblastoma [59].
Lineage-specific transcription factors have increasingly been
demonstrated as important tools in the diagnostic workup of a
range of tumor types including OCT4 and NANOG in peripheral
and CNS germ cell tumors[28,29], MYF4 in tumors with
myogenic differentiation[60], OLIG2 in tumors with glial
differentiation[61], TTF1 in thyroid tumors, BSAP (PAX5) in B-
cell neoplasms[62], Brachyury in chordomas [63] and hemangio-
blastomas [64] and CDX2 in gastrointestinal tumors[65]. CRX
represents a new addition to this group and suggests that
additional useful markers may be discovered through systematic
identification of lineage restricted transcription factors in a broader
range of tumors.
Figure 8. Expression profiling analysis demonstrates CRX expression is highly lineage-restricted across a broad range of cancer
tissues and cell lines. Analysis of CRX mRNA expression was assessed using publically available expression profiling data from over 1900 primary
tumor samples and demonstrates elevated expression of CRX predominantly in medulloblastoma samples (A). Pineal parenchymal tumor data is not
available. Oncomine data from 316 human cancer cell lines demonstrates 26 lines with significant expression of CRX relative to other lines as
demonstrated in a scatter plot (B). All expression levels are relative to the total dataset. The highest relative expression level was present in the sole
retinoblastoma cell line (Y79) within the dataset (C). High level expression was also noted in the only two medulloblastoma cell lines present in the
dataset (D341 and D283). Other CNS tumor cell lines showed no significant increase in CRX expression (8 astrocytoma, 1 PNET). Additional validation
using same independent normalization methods as for tissues produced similar results (Fig. S2). Data utilized in construction of plots is provided as
Tables S1 and S2.
doi:10.1371/journal.pone.0007932.g008
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seven genes are specifically expressed in pineoblastoma versus
other tumors of pineal parenchymal origin. Consistent with our
results showing that the frequency and intensity of expression of
CRX protein is similar in pineoblastoma, PPTID and pine-
ocytoma, CRX was not among the list of genes which
discriminated classes of pineal parenchymal tumors. Among the
seven discriminatory genes from Fevere-Montange et al., were the
three transcription factors HOXD13, PITX2 and POU4F2[25],
which unlike the highly lineage-restricted pattern of expression
seen for Crx, are expressed in lineage-nonrestricted patterns. The
use in tandem of both lineage-restricted and lineage-nonrestricted
transcription factors as components of a diagnostic panel has been
used in the evaluation of germ cells tumors where lineage-
restricted transcription factors like OCT4 and NANOG can be
used alongside lineage-nonrestricted transcription factors like
SOX2 [29] and SOX17[66]. This panel of transcription factors
permits, first, the confident identification of a germ cell tumor and
second, the more subtle discrimination between germ cell tumor
subclasses such as seminoma/germinoma, embryonal carcinoma,
yolk sac tumor and choriocarcinoma. The findings of Fevre-
Montagne et al. suggest that CRX along with HOXD13, PITX2
and POU4F2 might form the core transcription factor code
permitting an objective immunohistochemical and molecular
subclassification of pineal parenchymal tumors.
Within the field of cancer research, extensive effort continues to
be directed at identifying oncogene pathways that are activated in
cancer with the goal of developing targeted therapeutics to specific
signaling pathways. An emerging body of evidence, however,
supports the concept that tumors may also be dependent on the
same lineage-specific transcription factors which critically regulate
the normal tissue restricted developmental progenitor
cells[50,51,67]. This dependence for survival and proliferation
on critical cellular constituents that are not mutated and that alone
do not serve to transform cells (sometimes called ‘non-oncogene
addiction’) represents an under-explored opportunity for develop-
ment of targeted cancer therapies directed at these components
and pathways. Such pathways also have the added benefit of
reduced off-target effects due to their inherent lineage restriction.
Our study suggests CRX might represent just such a target in
retinoblastoma, pineoblastoma, and possibly even a subset of
medulloblastoma. Functional studies of CRX in these cancers
would certainly seem warranted, given the known dependency of
retinal and pineal lineage cells on this factor in humans and mice.
While no evidence of CRX alterations in cancer have yet been
described, its expression at high levels in these tumors also
warrants further investigation as to whether it might be a target for
rearrangement or amplification in cancers. Review of our
expression profiling data on cancer cell lines suggests that its
expression may be aberrantly regulated in several other cancers
not of the CNS lineage. Our identification of retinoblastoma and
medulloblastoma cell lines with CRX expression also represents an
opportunity for performance of further functional studies of CRX
in these specific human cell line systems given the lack of readily
available model systems for these cancers.
Supporting Information
Figure S1 Comparison of H120 antibody staining (Crx) with
RNA expression pattern of Otx1 and Otx2. Immunohistochem-
istry for Crx using H120 antibody in E14.5 mouse (A, B, C, brown
DAB) shows no overlap with the RNA expression pattern (purple,
BMPurple) of Otx1 (D, E, F) or Otx2 (G, H, I), including areas
with high level Otx expression such as the olfactory bulb and
cerebellum. This suggests that H120 is specific for Crx and does
not recognize the closest predicted family members.
Found at: doi:10.1371/journal.pone.0007932.s001 (2.18 MB TIF)
Figure S2 Meta-analysis of expression profiling in cancer cell
lines shows high level expression of CRX in retinoblastoma and
medulloblastoma cell lines. The Glaxo-Smith-Kline human cancer
cell line dataset was normalized and analyzed for expression of the
CRX specific probeset 217510. Highest expression was seen in two
medulloblastoma cell lines and the single retinoblastoma cell line
in the dataset. Most other cell lines showed little to no expression
of CRX.
Found at: doi:10.1371/journal.pone.0007932.s002 (2.52 MB TIF)
Table S1 CRX Expression in Human Tissues
Found at: doi:10.1371/journal.pone.0007932.s003 (0.23 MB
XLS)
Table S2 CRX Expression in Human Cell Lines
Found at: doi:10.1371/journal.pone.0007932.s004 (0.17 MB
XLS)
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